PARIS--(Marketwire - May 20, 2011) - The Medicines Company (NASDAQ: MDCO), a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines, today announced its partnership with Stent for Life, an initiative led by the coalition of European Association of Percutaneous Cardiovascular Interventions (EAPCI) and EuroPCR.
Efthymios Deliargyris, MD, Medical Director Europe for The Medicines Company, commented, “We are proud to be part of Stent for Life, working to improve access to immediate angioplasty for heart attack patients throughout Europe.”
Dr. Deliargyris spoke from the EuroPCR conference in Paris, where The Medicines Company’s anticoagulant Angiox® (bivalirudin) was featured in symposia discussing solutions for improved outcomes for patients undergoing PCI.
About Stent for Life
The Stent for Life Initiative was launched by the coalition of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and EuroPCR in 2009. The Stent for Life Initiative mission is to improve the delivery of care and patient access to the life saving indication of primary percutaneous coronary intervention (p-PCI), thereby reducing the mortality and morbidity of patients suffering from acute coronary syndrome (ACS).
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge intended to positively impact the well-being of critically ill patients. The Medicines Company’s website is www.themedicinescompany.com.
Contact:
Michael Mitchell
The Medicines Company
973-290-6000
investor.relations@themedco.com
